{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zimmer Biomet Holdings, Inc.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25, but has underperformed the S&P 500 with a year-to-date return of -2.32% and a five-year decline of 22.03%.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25 and has underperformed the S&P 500, showing a year-to-date return of -5.44% compared to the index's 16.30%.
Zimmer Biomet Holdings, Inc. Experiences Revision in Its Stock Evaluation Metrics
Zimmer Biomet Holdings, Inc. has recently adjusted its valuation, with a current P/E ratio of 25 and a price-to-book value of 2.25. The company has experienced a decline in return metrics over various periods, contrasting with the performance of the S&P 500 and its industry peers.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25, but has underperformed the S&P 500 with a year-to-date return of -4.80%.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25, making it more attractively priced than peers like Edwards Lifesciences and Agilent Technologies, despite underperforming the S&P 500 year-to-date.
Zimmer Biomet Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Zimmer Biomet Holdings, Inc. has recently seen a stock price of $95.09, reflecting volatility with a yearly high of $114.72 and a low of $89.22. The company's performance has lagged behind the S&P 500, with significant declines over the past year and longer periods, indicating competitive challenges.
Zimmer Biomet Stock Forms Golden Cross, Signaling Bullish Breakout Ahead
Zimmer Biomet Holdings, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. However, the company faces challenges, with a year-over-year stock decline and mixed technical indicators suggesting volatility in investor sentiment. The Golden Cross may signal a change in market perception.
Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?
As of October 10, 2025, Zimmer Biomet's technical trend is neutral with mixed indicators, showing a bearish MACD and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -10.34%.
Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?
As of October 10, 2025, Zimmer Biomet's technical trend is neutral with mixed indicators, showing a shift from mildly bearish to sideways, while it has underperformed the S&P 500 with a year-to-date return of -10.34% compared to the S&P's 11.41%.
Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?
As of August 4, 2025, Zimmer Biomet Holdings, Inc. has a mildly bearish trend, indicated by daily moving averages and weekly Dow Theory, despite mixed signals from the MACD and significant underperformance against the S&P 500.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of September 8, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25 and has underperformed the S&P 500, showing a year-to-date return of -5.13% compared to the index's 12.22%.
Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?
As of April 24, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25 and an EV to EBITDA ratio of 13.72, positioning it competitively within its industry despite a year-to-date return of -13.38%.
Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?
As of April 14, 2025, Zimmer Biomet Holdings, Inc. is in a bearish trend, with multiple indicators like the MACD, moving averages, and KST confirming this stance, despite some mixed signals from the RSI.
Who are in the management team of Zimmer Biomet Holdings, Inc.?
As of March 2022, the management team of Zimmer Biomet Holdings, Inc. includes Mr. Larry Glasscock (Independent Non-Executive Chairman), Mr. Bryan Hanson (President and CEO), and several Independent Directors: Mr. Christopher Begley, Ms. Betsy Bernard, Ms. Gail Boudreaux, and Mr. Michael Farrell. They oversee the company's strategic direction and operations.
What does Zimmer Biomet Holdings, Inc. do?
Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products and surgical solutions. As of March 2025, it reported net sales of $1.909 billion and a market cap of approximately $27.21 billion.
How big is Zimmer Biomet Holdings, Inc.?
As of Jun 18, Zimmer Biomet Holdings, Inc. has a market capitalization of $27.21 billion, with net sales of $7.70 billion and a net profit of $914.90 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
